secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001193125-23-081445
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Therapeutics reports FY 2022 net loss $31.2M, cash runway into Q4 2024
------------------------------------------------------------------------------

- Net loss for FY 2022 was $31.2M vs $16.2M in 2021; Q4 net loss $8.9M vs $4.3M.
- R&D expenses $23.9M in 2022, driven by ACR-368 Phase 2 trial and companion diagnostic agreement.
- Cash, cash equivalents and marketable securities $169.6M as of Dec 31, 2022; expected to fund operations at least into Q4 2024.
- FDA clearance received for IND of ACR-368 Phase 2 trial in platinum-resistant ovarian, endometrial, and urothelial cancers.
- Initial Phase 2 data expected in second half of 2023; WEE1 and PKMYT1 programs advancing toward IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/0001193125-23-081445-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523081445/d464039d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-081445

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer